Impact of Artificial Intelligence on Drug Discovery and Pharmacological Research

Abstract

Artificial Intelligence (AI) has emerged as a transformative technology in pharmaceutical sciences, revolutionizing drug discovery and pharmacological research through its ability to analyze vast and complex biological datasets with unprecedented speed and accuracy. Traditional drug discovery processes are often time-consuming, expensive, and associated with high failure rates, requiring several years and substantial financial investment to bring a new drug from laboratory development to clinical application. The integration of AI technologies, including machine learning, deep learning, natural language processing, and predictive analytics, has significantly accelerated various stages of drug development, enabling more efficient identification of drug targets, lead compounds, and therapeutic candidates. AI-driven computational models facilitate the analysis of genomic, proteomic, metabolomic, and clinical data, improving the understanding of disease mechanisms and supporting the development of personalized therapeutic strategies. In pharmacological research, AI has enhanced drug screening, molecular modeling, structure-based drug design, toxicity prediction, pharmacokinetic and pharmacodynamic analysis, and clinical trial optimization. Furthermore, AI-assisted drug repurposing has emerged as a cost-effective approach for identifying new therapeutic applications for existing medications, thereby reducing development timelines and costs.